ArticleCancer science2019

Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.

Wataru Munakata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.